Next Article in Journal
Physical Mapping of Stem Rust Resistance Gene Sr52 from Dasypyrum villosum Based on ph1b-Induced Homoeologous Recombination
Previous Article in Journal
The Systemic–Evolutionary Theory of the Origin of Cancer (SETOC): A New Interpretative Model of Cancer as a Complex Biological System
Previous Article in Special Issue
Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses
Open AccessReview

PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review

Department of Nuclear Medicine, AZ Groeninge, 8500 Kortrijk, Belgium
Department of Nuclear Medicine and Radiology, University Ghent, 9000 GHent, Belgium
Department of Nuclear Medicine, University of Pretoria, 0001 Pretoria, South-Africa
Laboratory of Drug Quality and Registration, University Ghent, 9000 Ghent, Belgium
Department of Imaging and Pathology, KULAK, University of Leuven, 3000 Leuven, Belgium
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(19), 4886;
Received: 2 September 2019 / Revised: 30 September 2019 / Accepted: 30 September 2019 / Published: 2 October 2019
(This article belongs to the Special Issue Cancer Molecular Imaging)
Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes. View Full-Text
Keywords: PSMA; positron emission tomography (PET); non prostate carcinoma PSMA; positron emission tomography (PET); non prostate carcinoma
MDPI and ACS Style

Van de Wiele, C.; Sathekge, M.; de Spiegeleer, B.; de Jonghe, P.J.; Beels, L.; Maes, A. PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review. Int. J. Mol. Sci. 2019, 20, 4886.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop